Eisai, Biogen and Alzheimer's disease
Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...
Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American ...
Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...
Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by ...
Eisai (ESALF) delivered another quarter with Leqembi growth, which is picking up strongly on a sequential basis. Read why I'm ...
Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions.
Health updates cover U.S. involvement in WHO meetings, UK approval of Moderna's RSV vaccine, a Texas measles outbreak, FDA ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback